课题基金 / 基金详情

A chikungunya Viral Replicon as a Platform for Antiviral Therapeutics

A chikungunya Viral Replicon as a Platform for Antiviral Therapeutics
基孔肯雅病毒复制子作为抗病毒治疗的平台
批准号：
8302538
负责人：
David E Levy
金额：
$40.51万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
项目状态：
已结题
起止时间：
2011-03-01 至 2014-02-28
来源：
https://reporter.nih.gov/project-details/8302538
关键词：
AdjuvantAntiviral AgentsAntiviral resistanceAreaBiochemicalCell LineCellsChikungunya virusCollaborationsCytoplasmDataDendritic CellsDevelopmentDiagnosticEffectivenessGene ExpressionGeneticImmune systemImmunityImpairmentInfectionInfluenza A virusInterferon Type IInterferonsKnowledgeMissionMolecularNatural ImmunityNatureNucleic AcidsPathway interactionsProteinsRepliconResearchSignal PathwaySignal TransductionSystemTherapeuticToll-like receptorsVaccinesVaccinia virusViralVirulenceVirulence FactorsVirusVirus DiseasesVirus InhibitorsWorkadaptive immunitybasebiodefensechikungunyadrug discoverygene inductionimmune resistancemembermicrobialnovel strategiesnovel therapeuticsreceptorresponsesmall moleculetherapeutic target

项目成果

David E Levy的其他基金

相似基金

相关文献

期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A chikungunya Viral Replicon as a Platform for Antiviral Therapeutics
Acquisition of an X-Rad 320 Biological Irradiator
Training Program in Molecular Oncology and Immunology
Genetic Analysis of Signaling Components in Innate Immunity
海外基金